TGF-β1 Reverses Inhibition of COX-2 With NS398 and Increases Invasion in Prostate Cancer Cells

被引:6
|
作者
Ding, Qiang [1 ]
Bai, Yu-Feng [1 ]
Wang, Yong-Quan [1 ]
An, Rui-Hua [1 ]
机构
[1] Harbin Med Coll, Dept Urol, Clin Coll 1, Harbin 150001, Peoples R China
来源
关键词
Prostate cancer; Cyclooxygenase-2; Growth factors; Prostaglandin-E2; Inhibitor; COLORECTAL-CARCINOMA CELLS; CYCLOOXYGENASE-2; EXPRESSION; MOLECULAR PATHOLOGY; SIGNALING PATHWAYS; STROMA INTERACTION; PROSTAGLANDIN E-2; BONE; DISEASE; GROWTH; PROLIFERATION;
D O I
10.1097/MAJ.0b013e3181d7c9db
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bone-derived transforming growth factor (TGF)-beta 1 leads to tumor growth, osteoblastic lesions and more invasion. Degradation of basement membranes caused by cyclooxygenase (COX)-2 is known as a distinctive feature of invasive cells. We investigated inhibition of COX-2 with NS398 in PC-3 and LNCaP cell lines. TGF-beta 1 and dmPGE2 were added in NS398 treated or untreated cells. COX-2 did not express in PC-3, after treatment with TGF-beta 1, COX-2 appeared and accompanied with enhanced invasion. COX-2 expressed in LNCaP, undetectable after addition of NS398 along with decreased invasion. Addition of TGF-beta 1 reversed inhibition of NS398 in both cell lines. DmPGE2 augmented invasion in both cell lines without alteration of COX-2. These results suggest that TGF-beta 1 can increase invasion and reverse inhibition of COX-2 induced by NS398. We indicate that bone-derived TGF-beta 1 might contribute to clinical unsatisfied effect of NSAIDs or COX-2 specific inhibitors adjuvant therapies. Our data provide a new potential therapy for fighting against prostate cancer.
引用
收藏
页码:425 / 432
页数:8
相关论文
共 50 条
  • [41] Breaking barriers for T cells by targeting the EPHA2/TGF-β/COX-2 axis in pancreatic cancer
    Conejo-Garcia, Jose R.
    JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (09): : 3521 - 3523
  • [42] Chronic co-treatment of NS398 (COX-2 inhibitor) with MTEP changes strategy of mice in Barnes Maze, through membrane resistance variation
    Stachowicz, K.
    Bobula, B.
    Kusek, M.
    Tokarski, K.
    Sowa-Kucma, M.
    Misztak, P.
    Panczyszyn-Trzewik, P.
    Pilc, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S88 - S89
  • [43] Novel combination of a COX-2 inhibitor, NS398, and MEK inhibitor, U0126, in human hepatocellular carcinoma provides synergistic increase in apoptosis
    Schmidt, CM
    Wang, YF
    Wiesenauer, C
    Yip-Schneider, M
    Wu, M
    GASTROENTEROLOGY, 2003, 124 (04) : A793 - A794
  • [44] COX-2选择性抑制剂NS398在小鼠皮肤光老化中的实验研究
    张璃
    梁虹
    徐世正
    姚莹
    医学临床研究, 2005, (08) : 1070 - 1072
  • [45] Inhibition of FAS (fatty acid synthase) expression by genistein and Cox-2 inhibitor (NS-398) in breast cancer cell lines.
    Yoon, DS
    Yim, JS
    Song, KH
    Kwon, HW
    Ko, DG
    Choi, IS
    Choi, WJ
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (11) : 2749S - 2749S
  • [46] COX-2 inhibition reverses leptin-stimulated breast cancer growth in vitro
    Somasundar, P
    Vona-Davis, LC
    Riggs, D
    Jackson, B
    McFadden, DW
    GASTROENTEROLOGY, 2003, 124 (04) : A611 - A611
  • [47] TGF-β1 Downregulates COX-2 Expression Leading to Decrease of PGE2 Production in Human Lung Cancer A549 Cells, Which Is Involved in Fibrotic Response to TGF-β1
    Takai, Erina
    Tsukimoto, Mitsutoshi
    Kojima, Shuji
    PLOS ONE, 2013, 8 (10):
  • [48] Cyclooxygenase-1 (COX-1), but not COX-2, inhibition increases acid secretion in rabbit parietal cells (PC)
    Nandi, J
    Das, PK
    Baltodano, JD
    Finocchiaro, S
    Arif, MO
    Levine, RA
    FASEB JOURNAL, 2005, 19 (04): : A755 - A755
  • [49] Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor
    Yamamoto, T
    NozakiTaguchi, N
    BRAIN RESEARCH, 1996, 739 (1-2) : 104 - 110
  • [50] Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells
    Wen, BX
    Deutsch, E
    Eschwege, P
    De Crevoisier, R
    Nasr, E
    Eschwege, F
    Bourhis, J
    JOURNAL OF UROLOGY, 2003, 170 (05): : 2036 - 2039